價格 | ¥398 | ¥578 | ¥788 |
包裝 | 1mg | 2mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-02 |
中文名稱:化合物 LDN-193189 | 英文名稱:LDN193189 |
CAS:1062368-24-4 | 品牌: TargetMol |
產地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.86% | 產品類別: 抑制劑 |
貨號: T1935 |
名稱 | LDN193189 |
描述 | LDN193189 (DM-3189) is a selective inhibitor of the BMP type I receptor that inhibits ALK2 and ALK3 (IC50=5/30 nM), with less activity against ALK4, ALK5, and ALK7. LDN193189 can be used in studies of progressive ossifying fibrous dysplasia. |
細胞實驗 | C2C12 cells were seeded into 96-well plates at 2,000 cells per well in DMEM supplemented with 2% FBS. We treated the wells in quadruplicate with BMP ligands and LDN-193189 or vehicle. We collected the cells after 6 d in culture in 50 μl Tris-buffered saline and 1% Triton X-100. We added the lysates to p-nitro-phenylphosphate reagent in 96-well plates for 1 h and then evaluated alkaline phosphatase activity (absorbance at 405 nm). We measured cell viability and quantity by Cell Titer Aqueous One (absorbance at 490 nm), using replicate wells treated identically to those used for alkaline phosphatase measurements [1]. |
動物實驗 | In the first experiment, SCID mice were implanted with MDA-PCa-118b tumors. After 7 days when tumors reached measurable sizes, mice were injected with LDN-193189 (3 mg/kg) or with vehicle intraperitoneally twice a day. Tumor sizes and body weights were measured weekly. Mice were injected with calcein at three days and one day prior to sacrifice. Blood was collected and tumors were weighed. A portion of the tumors were fixed in formaldehyde for micro-computed tomography, using EVS CT, or further decalcified for bone histomorphometric analysis, using the OsteoMeasure Analysis System, or flash frozen for RNA preparation. Osteocalcin in the mouse serum was determined by ELISA. In the second experiment, PCa-118b tumors were first digested with Accumax, and the isolated cells were plated overnight, digested by Accutase, resuspended in Matrigel in 1:1 ratio, and injected into SCID mice (1 × 10^6 cells/mouse) subcutaneously. Mice were treated with LDN-193189 five days post-injection [3]. |
體外活性 | 方法:肺動脈平滑肌細胞 PASMCs 用 LDN193189 (2-32000 nM) 預處理 10 min,再用 BMP4 (10 ng/mL) 或 TGF-β (0.5 ng/mL) 處理 30 min,使用 Western Blot 檢測靶點蛋白表達水平。 結果:用 LDN193189 處理的 PASMC 的顯示對 BMP4 或 TGF-β 信號傳導的不同抑制,IC50 分別為 5 nM 和 ≥1 μM。[1] 方法:未分化的 C2C12 細胞用 Smad3/4 反應性 (CAGA)12-熒光素酶或 Smad1/5 反應性 BRE 熒光素酶報道基因構建體連同組成型表達的海腎熒光素酶轉染過夜。細胞被血清饑餓,并用 LDN193189 (0.05-5 μM) 和 GDF8、TGF-β 或 BMP2 處理 6 h,檢測熒光素酶活性。 結果:LDN193189 從 0.05 μM 抑制 GDF8 誘導的 (CAGA)12-熒光素酶活性。0.05 μM 的 LDN193189 可有效抑制 BMP2 誘導的 BRE 熒光素酶活性。TGF-β誘導的 (CAGA)12-熒光素酶活性被 0.5 μM 的 LDN193189 抑制。[2] |
體內活性 | 方法:為研究 ALK2 激酶抑制對體內異位鈣化的影響,將 LDN193189 (3 mg/kg) 腹腔注射給 caALK2 轉基因和野生型小鼠,每 12 h 一次,持續(xù) 60 天。 結果:在 P30 時,LDN193189 在大約三分之二的小鼠中預防了異位骨,并減輕了其余小鼠的損傷。而在 P60 時,LDN193189 在三分之一的小鼠中防止了異位骨并減輕了剩余小鼠的損傷。[1] |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | H2O : Insoluble DMSO : 1.45 mg/mL (3.56 mM), when pH is adjusted to 2 with HCl. Sonication is recommended. 0.01M HCL : 1.67 mg/mL (4.1 mM) |
關鍵字 | Inhibitor | Transforming growth factor beta receptors | inhibit | DM3189 | LDN193189 | DM 3189 | TGF-β Receptor |
相關產品 | Monocrotaline | Pirfenidone | Ceritinib | A 83-01 | Chromenone 1 | LY-364947 | BMP signaling agonist sb4 | Alectinib hydrochloride | SB-431542 | Galunisertib | Alantolactone | Hydrochlorothiazide |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.2651萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 化學試劑,生物活性小分子 | 經營模式 | 貿易,試劑,定制,服務 |
產品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP6年
|
上海澤葉生物科技有限公司
|
2025-02-10 | |
¥11 |
VIP4年
|
湖北科樂精細化工有限公司
|
2025-02-10 | |
¥3089.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-01-20 | |
¥700 |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
詢價 |
北京凱默林生物科技
|
2016-04-06 | ||
詢價 |
ChemScene, LLC
|
2012-12-11 | ||
詢價 |
-
|
2011-06-01 |